Anyone interested in Nektar Therapeutics (NASDAQ:NKTR) should probably be aware that the CEO, President & Director, Howard Robin, recently divested US$144k worth of shares in the company, at an average price of US$3.95 each. The eyebrow raising move amounted to a reduction of 12% in their holding.
